Clinical Trial Update: Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of Iressa (gefitinib) in patients with poor performance status and previously untreated advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED